On April 30, 2025 Starpharma, an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, reported its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2025 (Q3 FY25) (Press release, Starpharma, APR 30, 2025, View Source [SID1234654130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Starpharma’s Chief Executive Officer, Cheryl Maley, commented:
"It is almost 12 months since we announced our revised strategy. We have made significant progress towards achieving our objectives during this time, and we acknowledge that some outcomes are taking longer than we initially anticipated. The Starpharma team remains intensely focused on delivering on our strategic priorities, and we are committed to achieving the outcomes agreed with the Board in May 2024 with a high sense of urgency. Earlier this month, the Board and Leadership team convened to reflect on Starpharma’s progress and to reaffirm our strategic direction going forward

"Our top priorities this quarter have been to advance existing and potential new partnerships, develop the clinical program for DEP SN38 to get to market in the most time- and commerciallyeffective way and build robust pre-clinical data in our radio program that exemplifies the benefits of our dendrimer technology in radiopharmaceuticals.

"The dual goals of our radio program over the past months have focused on creating valuable preclinical data for the development of further enhanced HER2 assets and compelling data for potential partners interested in the application of the DEP platform to radiopharmaceuticals. This will delay the commencement of our clinical program; however, we are excited about the data generated thus far and the potential opportunities to partner in this area.

"This past quarter, we also launched new promotions for Viraleze in the UK and developed a program to make VivaGel BV available online in Europe in FY26.

"We continue managing costs effectively through clear prioritisation, resource management and implementing cost-saving strategies, whilst focusing on revenue generation opportunities such as partner licensing of the DEP platform and assets and product sales for Viraleze and VivaGel BV. We are also enhancing efficiency in drug development by leveraging outsourcing, automation, and exploring the use of AI.

"Whilst the past few months have been challenging across many sectors, including the Australian Biotech sector, we are confident that our versatile platform drug delivery technology offers multiple opportunities for value generation through partnerships and innovative asset development, which we aim to maximise through our strategic priorities.

"I would like to thank our shareholders for your patience and ongoing support as we work diligently to restore value to Starpharma investors."

On April 30, 2025 Otsuka reported consolidated financial results for the three-month period ended March 31, 2025 (Filing, 3 mnth, MAR 31, Otsuka, 2025, APR 30, 2025, View Source [SID1234654081]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 30, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported clinical data from the pivotal Phase 3 study of its lead product candidate, Bria-IMT, in metastatic breast cancer (BRIA-ABC; NCT06072612 ) supporting the use of specific biomarkers to predict patients’ clinical response to Bria-IMT treatments (Press release, BriaCell Therapeutics, APR 30, 2025, View Source [SID1234652434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits with BriaCell’s novel Bria-IMT regimen.

"Using biomarkers as powerful instruments to predict patient responsiveness to the Bria-IMT treatment would allow physicians and oncologists to identify potential responders sooner, providing better clinical outcomes and ultimately extending patients’ lives," stated Carmen Calfa, MD, Clinical Research Lead for the breast site disease group at the University of Miami Miller School of Medicine, Co-Director of the Cancer Survivorship Program at Sylvester Comprehensive Cancer Center, and Principal Clinical Investigator of the Phase 2 Bria-IMT study.

"We are very pleased with our early Phase 3 biomarker data highlighting their importance as important tools in BriaCell’s fight against metastatic breast cancer, a difficult to treat and deadly disease," stated Dr. William V. Williams, BriaCell’s President & CEO.

"The clinical data reported today demonstrates the potential use of certain key biomarkers to predict MBC patients’ clinical response to the Bria-IMT regimen," noted Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. "We will continue to evaluate these findings as we advance our goal of treating this serious disease."

The poster is summarized below and linked here: View Source .

Title: Bria-ABC [1] vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trial
Session Title: Late-Breaking Research: Clinical Research 4
Session Date and Time: 4/30/2025 9:00 AM – 12:00 PM CST
Location: Poster Section 49
Poster Board Number: 14
Abstract Presentation Number: LB408

Kaplan Meier analysis of early clinical data (n=62) in this multicenter study showed median progression free survival across all arms of 3.67 months. Prespecified subset analyses of PFS based on biomarker status were reported as follows:

Positive DTH was significantly related to better PFS (4.5 vs 2.5 months, p = 0.001)
Neutrophil-to-lymphocyte ratio (NLR) < 0.7 and ≥ 2.3 following the 1st treatment administration had significantly lower (p = 0.02) median progression-free survival (PFS)
Circulating tumor cells (CTCs) < 1 were significantly related to better PFS values (3.8 months vs 2.4 vs, p = 0.04)
Baseline Cancer-Associated Macrophage-Like Cells (CAML) count ≥ 5 trended toward a higher PFS value (3.7 vs 2.2 months, p = 0.10)
The Bria-IMT regimen remains well-tolerated, with generally manageable treatment-emergent adverse events (TEAEs). There have been no Bria-IMT related treatment discontinuations, underscoring Bria-IMT’s excellent tolerability and favorable safety profile.

About the Bria-ABC Study

The multicenter randomized open label study is evaluating overall survival with the Bria-IMT regimen in combination with checkpoint inhibitor, versus Treatment of Patients’/Physicians’ Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available. Fifty-seven clinical sites in the US are actively enrolling patients and additional sites are in various stages of start-up.

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. BriaCell recently announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen . The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612 .

On April 30, 2025 Capstan Therapeutics, Inc. ("Capstan"), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), reported that the Company will present at upcoming scientific conferences and showcase new preclinical data on CPTX2309, Capstan’s lead anti-CD19 in vivo CAR-T candidate, at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting in New Orleans, LA (Press release, Capstan Therapeutics, APR 30, 2025, View Source [SID1234652404]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Among the diverse set of presentations showcasing Capstan’s non-viral CellSeeker platform, we are particularly encouraged by new preclinical data in support of our in vivo anti-CD19 CAR-T program, which demonstrate that a compact two-dose cycle was sufficient to induce rapid and deep B cell depletion in blood and tissues of non-human primates," said Adrian Bot, M.D., Ph.D., Chief Scientific Officer and Executive Vice President of R&D at Capstan. "These preclinical data highlight the potency of B cell depletion achievable with a transient in vivo CAR mRNA approach, without the need for lymphodepletion, and set the stage for clinical evaluation of CPTX2309."

Featured Presentation:

American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting
Date: May 13-17, 2025
Location: New Orleans, LA

Oral presentation title: A Two-Infusion Regimen with a Novel In Vivo Non-Viral Chimeric Antigen Receptor (CAR) Achieves up to 90% CD8+ T Cell Engineering and Tissue Depletion of Target Cells in Non-Human Primates (NHPs)
Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder
Session title: CAR T Innovations in Autoimmune and Infectious Disease and Allergy
Date and time: May 15, 2025, 5:00 p.m. – 5:15 p.m. CT
Location: Room 393-396

Additional Presentations feature progress with our CellSeekerTM platform technology applicable to both mRNA and gene editing payloads:

Cellicon Valley ’25: The Future of Cell and Gene Therapies
Date: Apr 30-May 2, 2025
Location: Philadelphia, PA

Oral Presentation Title: Leading the Charge for In Vivo Cell Therapy for The Treatment of Autoimmune Disorders
Presenter: Laura Shawver, Ph.D., Chief Executive Officer
Session title: Plenary Session 2, Leadership in Cell and Gene Therapies: The XX Factor
Date and Time: May 1, 2025, 10:20 a.m. – 10:30 a.m. ET

International Society of Cell & Gene Therapy (ISCT) 2025
Date: May 7-10, 2025
Location: New Orleans, LA

Poster title: Design and Preclinical Development of a Novel In Vivo Chimeric Antigen Receptor (CAR) Product for B-Cell Involved Diseases
Presenter: Haig Aghajanian, Ph.D., Vice President of Research, Co-founder
Poster number: 901
Session title: Poster Networking Reception 1; Immunotherapy (CAR-T, T Reg, NK Cells, etc.)
Date and time: May 7, 2025, 7:00 p.m. – 8.30 p.m. CT

21st Annual PEGS Boston: The Essential Protein & Antibody Engineering Summit
Date: May 12-16, 2025
Location: Omni Boston Hotel at the Seaport, Boston, MA

Title: Chairperson’s Remarks
Presenter: Adrian Bot, M.D., Ph.D., Chief Scientific Officer
Track: In Vivo CAR T Engineering: Moving into the Clinic
Date and time: May 15, 2025, 8:25 a.m. ET

Oral presentation title: In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders
Presenter: John Rossi, Vice President, Translational Medicine
Track: In Vivo CAR T Engineering: Moving into the Clinic
Date and time: May 15, 2025, 9:00 a.m. ET

American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting
Date: May 13-17, 2025
Location: New Orleans, LA

Science Symposium: Targeted Nanosystems For Gene Transfer And Editing: Beyond Delivery To The Liver
Oral presentation title: In vivo immune cell engineering using targeted nanoparticles
Presenter: Priya Karmali, Ph.D., Chief Technology Officer
Date and time: May 16, 2025, 4:10 p.m. – 4:35 p.m. CT
Location: NOLA Theater B

Poster: Efficient In Vivo Gene Editing of T Cells Utilizing Novel Targeted Lipid Nanoparticles
Presenter: Esther Chen, Ph.D., Principal Scientist, R&D
Session title: Tuesday Poster Reception
Date and time: May 13, 2025, 6:00 p.m. – 7:30 p.m. CT
Location: Poster Hall I2

Poster: Effective Gene Editing in Hematopoietic Stem and Progenitor Cells (HSPCs) through a Novel Targeted Lipid Nanoparticle
Presenter: Esther Chen, Ph.D., Principal Scientist, R&D
Session title: Thursday Poster Reception
Date and time: May 15, 2025, 5:30 p.m. – 7:00 p.m. CT
Location: Poster Hall I2

TIDES USA
Date: May 19-22, 2025
Location: Manchester Grand Hyatt San Diego, San Diego, CA

Oral presentation title: In Vivo Engineering of Cells Using Targeted Lipid Nanoparticles
Presenter: Priya Karmali, Ph.D., Chief Technology Officer
Track: mRNA Technology and Applications
Date and time: May 21, 2025, 2:00 p.m. PT

On April 30, 2025 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, reported preliminary financial results for Q1 2025 and that it has entered into a securities purchase agreement with certain investors for shares of its common stock to raise approximately $22.0 million in gross proceeds (Press release, TriSalus Life Sciences, APR 30, 2025, View Source [SID1234652403]). Additionally, as further described below, the Company committed to commence an exchange offer with respect to its outstanding Series A Convertible Preferred Stock (the "Preferred Stock"), which is intended to simplify the Company’s capital structure.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preliminary Unaudited First Quarter 2025 Financial Results

Full financial results for the quarter ended March 31, 2025 are in the process of being finalized, however, initial and preliminary results show revenue, driven solely by the TriNav Infusion System, of approximately $9.2 million for the first quarter of 2025. This represents growth of approximately 42% versus the first quarter of 2024.

Private Placement

The private placement is being led by Nantahala Capital and includes investments by Broadfin Holdings and additional healthcare-focused institutional investors. Canaccord Genuity is acting as the sole placement agent for the private placement.

The Company will issue an aggregate of 5,500,000 shares of its common stock at a purchase price of $4.00 per share. The private placement is expected to close on or about May 2, 2025, subject to satisfaction of customary closing conditions. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock issued in the private placement and intends to use the net proceeds from the private placement for working capital and general corporate purposes.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws.

Simplifying the Capital Structure

In connection with the private placement, TriSalus has entered into a Tender and Support Agreement with certain holders representing approximately 55% of outstanding shares of Preferred Stock. The Company has agreed to:

Launch a registered exchange offer pursuant to a registration statement on Form S-4 to be filed with the SEC to offer all preferred holders the opportunity to exchange their shares of Preferred Stock into a number of shares of common stock calculated based on a fixed value of $10.00 per share of Preferred Stock plus accrued dividends that would have accrued through August 10, 2027, divided by $4.00 per share; and
Convene a special meeting of stockholders to, among other things, vote on an amendment to the Certificate of Designations for the Preferred Stock that would (i) allow TriSalus to call and convert outstanding shares of Preferred Stock under specific terms and (ii) eliminate the conversion price reset provision currently scheduled for July 2027.
The Company expects to launch the exchange offer by the end of the second quarter of 2025 and to hold the special meeting in the third quarter of 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Preliminary Financial Results

The preliminary results set forth above are unaudited, are based on management’s initial review of the Company’s results for the quarter ended March 31, 2025, and are subject to revision based upon the Company’s quarter-end closing procedures. Actual results may differ materially from these preliminary unaudited results following the completion of quarter-end closing procedures, final adjustments or other developments arising between now and the time that the Company’s financial results are finalized. In addition, these preliminary unaudited results are not a comprehensive statement of the Company’s financial results for the quarter ended March 31, 2025, should not be viewed as a substitute for full, unaudited financial statements for the quarter ended March 31, 2025, and are not necessarily indicative of the Company’s results for any future period.